ACB

Curaleaf Holdings raised its hostile takeover bid for Aurora Cannabis to $1 cash and 0.4013 shares per share, valuing the deal at $5-6 per share, but Aurora's board rejected it again. While Curaleaf's H1 2026 revenues grew 8% to $664.3 million with expanding retail presence and strong international growth, margin pressures and rising operating expenses remain concerns. The company targets $35-40 million in SG&A savings, but faces intense competition from Green Thumb Industries and TerrAscend.

Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.

Curaleaf launched a hostile takeover bid for Aurora Cannabis at $4 per share in August 2026, which Aurora rejected as undervalued. The situation has escalated with Curaleaf attempting to block Aurora's ability to raise capital through stock sales. With the tender offer open until December 1, significant animosity between the companies makes integration difficult if the acquisition succeeds, while Aurora shareholders face uncertainty about whether to accept the offer or hold for potential higher valuations.